APN-01 is under clinical development by APEIRON Biologics and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData, Phase II drugs for Pulmonary Arterial Hypertension have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APN-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APN-01 is under development for the treatment of acute lung injury, acute respiratory distress syndrome, pulmonary arterial hypertension and Coronavirus infection (COVID-19). It is administered intravenously as a solution. The drug candidate is a recombinant human angiotensin converting enzyme 2 (rhACE2).
APEIRON Biologics overview
APEIRON Biologics (APEIRON) is a clinical-stage biotechnology company that concentrates on the development of biological and immunological solutions for the treatment of various cancers. The company’s pipeline products include APN01, APN301, APN311, APN401, APN411, APN421 and APN431. Its APN311 is an antibody-based therapy used for the treatment of high-risk neuroblastoma. APEIRON’s APN301 is an anti-GD2 antibody-IL2 fusion protein used for intratumoral application in GD2+ pediatric cancers. The company carries out projects in the biotherapy and cancer immune field. APEIRON is headquartered in Vienna, Austria.
For a complete picture of APN-01’s drug-specific PTSR and LoA scores, buy the report here.